RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $580
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Trung Huynh has maintained an 'Outperform' rating on Eli Lilly (NYSE:LLY) and raised the price target from $490 to $580.
August 09, 2023 | 11:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's price target has been raised from $490 to $580 by RBC Capital, maintaining an 'Outperform' rating.
The raised price target and maintained 'Outperform' rating by RBC Capital indicates a positive outlook for Eli Lilly. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100